JP2024023232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023232A5 JP2024023232A5 JP2023189072A JP2023189072A JP2024023232A5 JP 2024023232 A5 JP2024023232 A5 JP 2024023232A5 JP 2023189072 A JP2023189072 A JP 2023189072A JP 2023189072 A JP2023189072 A JP 2023189072A JP 2024023232 A5 JP2024023232 A5 JP 2024023232A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- identity
- nucleic acid
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 73
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 68
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 60
- 108020004707 nucleic acids Proteins 0.000 claims description 59
- 102000039446 nucleic acids Human genes 0.000 claims description 59
- 230000011664 signaling Effects 0.000 claims description 46
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 43
- 102100023123 Mucin-16 Human genes 0.000 claims description 43
- 102000001301 EGF receptor Human genes 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 239000012642 immune effector Substances 0.000 claims description 29
- 229940121354 immunomodulator Drugs 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 230000000139 costimulatory effect Effects 0.000 claims description 25
- 108060006698 EGF receptor Proteins 0.000 claims description 24
- 102000003812 Interleukin-15 Human genes 0.000 claims description 21
- 108090000172 Interleukin-15 Proteins 0.000 claims description 21
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 240000007019 Oxalis corniculata Species 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 102000008579 Transposases Human genes 0.000 claims description 7
- 108010020764 Transposases Proteins 0.000 claims description 7
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 230000002611 ovarian Effects 0.000 claims description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241001648840 Thosea asigna virus Species 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 108010057988 ecdysone receptor Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680297P | 2018-06-04 | 2018-06-04 | |
| US62/680,297 | 2018-06-04 | ||
| JP2020567215A JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| PCT/US2019/035384 WO2019236577A2 (en) | 2018-06-04 | 2019-06-04 | Muc16 specific chimeric antigen receptors and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Division JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023232A JP2024023232A (ja) | 2024-02-21 |
| JP2024023232A5 true JP2024023232A5 (enExample) | 2024-10-16 |
Family
ID=68764543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2023189072A Pending JP2024023232A (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11319380B2 (enExample) |
| EP (1) | EP3802615A4 (enExample) |
| JP (2) | JP2021525534A (enExample) |
| KR (1) | KR20210021493A (enExample) |
| CN (1) | CN112533957A (enExample) |
| AU (1) | AU2019282620A1 (enExample) |
| CA (1) | CA3101641A1 (enExample) |
| IL (1) | IL278976A (enExample) |
| SG (1) | SG11202011895VA (enExample) |
| WO (1) | WO2019236577A2 (enExample) |
| ZA (3) | ZA202008065B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2018352984B2 (en) * | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| JPWO2021256522A1 (enExample) * | 2020-06-17 | 2021-12-23 | ||
| JP2024500189A (ja) * | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| AU2022211438A1 (en) * | 2021-01-19 | 2023-08-17 | Obsidian Therapeutics, Inc. | Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof |
| US20250145950A1 (en) * | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN115819613B (zh) * | 2022-05-10 | 2023-10-20 | 四川大学华西医院 | 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1536814A4 (en) | 2002-07-03 | 2006-02-15 | Immunogen Inc | ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF |
| RU2430112C2 (ru) | 2005-06-20 | 2011-09-27 | Дженентек, Инк. | Композиции и способы диагностики и лечения опухоли |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| EP2245156A4 (en) | 2008-01-11 | 2011-02-02 | Gene Techno Science Co Ltd | HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF |
| ES2911246T3 (es) * | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| ES2621874T3 (es) * | 2010-03-26 | 2017-07-05 | Memorial Sloan-Kettering Cancer Center | Anticuerpos para MUC16 y métodos de uso de los mismos |
| DK2981607T3 (da) | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
| KR102238226B1 (ko) * | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| ES2765710T3 (es) * | 2014-04-03 | 2020-06-10 | Cellectis | Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer |
| WO2016014565A2 (en) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| EP3273994B1 (en) | 2015-03-27 | 2021-12-01 | University of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| CN108064246A (zh) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| EP3344284A1 (en) | 2015-09-04 | 2018-07-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11787848B2 (en) * | 2016-06-08 | 2023-10-17 | Precigen, Inc. | CD33 specific chimeric antigen receptors |
| WO2018009811A1 (en) * | 2016-07-08 | 2018-01-11 | Genentech, Inc. | Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment |
| JP7295795B2 (ja) | 2016-07-29 | 2023-06-21 | ジュノー セラピューティクス インコーポレイテッド | 免疫調節ポリペプチドならびに関連する組成物および方法 |
| EP3522933B1 (en) * | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
-
2019
- 2019-06-04 CA CA3101641A patent/CA3101641A1/en active Pending
- 2019-06-04 WO PCT/US2019/035384 patent/WO2019236577A2/en not_active Ceased
- 2019-06-04 CN CN201980052129.8A patent/CN112533957A/zh active Pending
- 2019-06-04 EP EP19815389.2A patent/EP3802615A4/en active Pending
- 2019-06-04 JP JP2020567215A patent/JP2021525534A/ja active Pending
- 2019-06-04 AU AU2019282620A patent/AU2019282620A1/en active Pending
- 2019-06-04 US US16/431,193 patent/US11319380B2/en active Active
- 2019-06-04 SG SG11202011895VA patent/SG11202011895VA/en unknown
- 2019-06-04 KR KR1020207038033A patent/KR20210021493A/ko not_active Ceased
-
2020
- 2020-11-25 IL IL278976A patent/IL278976A/en unknown
- 2020-12-23 ZA ZA2020/08065A patent/ZA202008065B/en unknown
-
2021
- 2021-12-22 ZA ZA2021/10780A patent/ZA202110780B/en unknown
-
2022
- 2022-02-04 US US17/650,018 patent/US11981746B2/en active Active
- 2022-02-04 US US17/650,025 patent/US11976134B2/en active Active
-
2023
- 2023-11-06 JP JP2023189072A patent/JP2024023232A/ja active Pending
- 2023-12-19 ZA ZA2023/11718A patent/ZA202311718B/en unknown
-
2024
- 2024-04-05 US US18/628,575 patent/US20240368305A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023232A5 (enExample) | ||
| US12371489B2 (en) | Car based immunotherapy | |
| US9868961B2 (en) | Methods and compositions for localized secretion of anti-CTLA-4 antibodies | |
| JP2024138280A5 (enExample) | ||
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| Song et al. | OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen | |
| Liu et al. | Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells | |
| EP3599251A1 (en) | Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof | |
| JP7636650B2 (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| KR20180057723A (ko) | 항-cd30 키메라성 항원 수용체 | |
| JP7431735B2 (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| AU2018385694B2 (en) | NKG2D DARIC receptors | |
| EP4534561A1 (en) | Bispecific chimeric antigen receptor targeting bcma-cd19 and application thereof | |
| CN107936120A (zh) | Cd19靶向性的嵌合抗原受体及其制法和应用 | |
| JPWO2019236577A5 (enExample) | ||
| WO2023093888A1 (zh) | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 | |
| CN116410331B (zh) | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 | |
| US20250387483A1 (en) | Bispecific chimeric antigen receptor targeting bcma-cd19 and application thereof | |
| CN109593137B (zh) | 抗cd20抗体的新型cd20-car载体的构建及应用 | |
| HK40123857A (en) | Bispecific chimeric antigen receptor targeting bcma-cd19 and application thereof | |
| WO2024179518A1 (zh) | 具有优化的itam结构域及cd28与4-1bb双共刺激分子的双靶点car-t | |
| WO2024190856A1 (ja) | 抗ｂｃｍａ抗体およびキメラ抗原受容体 | |
| KR20240111378A (ko) | Nkg2d 키메라 수용체, 이를 발현하는 형질전환 세포 및 이의 항암 용도 |